Purpose BRCA1/2 mutations are well-known risk factors for breast and ovarian cancers in women. Risk-reducing salpingo-oophorectomy (RRSO) is the standard treatment for preventing ovarian cancer with BRCA mutations. Postmenopausal syndrome (symptoms after RRSO can be alleviated by hormone replacement therapy (HRT); however, the use of HRT in carriers of BRCA mutations has been controversial because of the concern that HRT increases the risk of breast cancer. This study aimed to evaluate the effects of HRT in BRCA mutation carriers who underwent RRSO.
Materials and Methods A total of 151 carriers, who underwent RRSO between 2013 and 2020 after the diagnosis of BRCA1 or BRCA2 mutations were selected and followed up for a median of 3.03 years. Patients were divided into two groups: those who received HRT after RRSO (n=33) and those who did not (n=118). We compared the incidence of breast cancer over time between these two groups.
Results There was no significant difference in the incidence of breast cancer between women who received HRT and those who did not (p=0.229). Multivariate logistic regression analysis, adjusted for age and parity revealed no significant difference in the risk of breast cancer between these two groups (hazard ratio, 0.312; 95% confidence interval, 0.039 to 2.480; p=0.278).
Conclusion In this study, we found no relationship between post-RRSO HRT and breast cancer in the population with BRCA mutations. Therefore, healthcare providers may consider the alleviation of symptoms of postmenopausal syndrome through HRT in patients who underwent RRSO.
Citations
Citations to this article as recorded by
A contemporary review of breast cancer risk factors and the role of artificial intelligence Orietta Nicolis, Denisse De Los Angeles, Carla Taramasco Frontiers in Oncology.2024;[Epub] CrossRef
Purpose
The study aimed to evaluate the diagnostic accuracy of polymerase chain reaction ‒based high-risk human papillomavirus (HPV) assays on self-collected vaginal and urine samples for detection of precancerous cervical lesions in referral population.
Materials and Methods
Women referred for colposcopy following abnormal cytology, were included this study. A total of 314 matched urine, vaginal, and cervical samples were collected. All samples were tested for HPV DNA using the RealTime HR-S HPV and Anyplex II HPV 28 assays. Primary endpoints were sensitivity for cervical intraepithelial neoplasia (CIN) 2+/CIN3+ and specificity for Result
The sensitivity of Realtime HR-S and Anyplex HPV assay was 93.13% (95% confidence interval [CI], 87.36 to 96.81) and 90.08% (95% CI, 83.63 to 94.61) for CIN2+ (n=130); specificity for Conclusion
The detection performance for hrHPV and CIN2+ on self-collected vaginal samples was comparable to that of clinician-collected cervical samples. On the other hand, HPV tests using urine were inferior to those using clinician-collected cervical samples in terms of detecting hrHPV and CIN2+.
Citations
Citations to this article as recorded by
Variables that impact HPV test accuracy during vaginal self collection workflow for cervical cancer screening Laurence Vaughan, Devin Gary, Millie Shah, Lyndsay Lewellen, Laura Galbraith, Valentin Parvu Gynecologic Oncology Reports.2024; 54: 101421. CrossRef
Clinical performance of a newly developed domestic urine‐based HPV test for cervical cancer screening in China Hui‐Fang Xu, Xue‐Lian Zhao, Shuang Zhao, Shang‐Ying Hu, Xun Zhang, Fang‐Hui Zhao, You‐Lin Qiao Journal of Medical Virology.2023;[Epub] CrossRef
Can HPV Test on Random Urine Replace Self-HPV Test on Vaginal Self-Samples or Clinician-Collected Cervical Samples? Yu-Hsiang Shih, Lou Sun, Shih-Tien Hsu, Ming-Jer Chen, Chien-Hsing Lu International Journal of Women's Health.2023; Volume 15: 1421. CrossRef
Preliminary Results of Feasibility and Acceptability of Self-Collection for Cervical Screening in Italian Women Illari Sechi, Narcisa Muresu, Mariangela V. Puci, Laura Saderi, Arcadia Del Rio, Andrea Cossu, Maria R. Muroni, Santina Castriciano, Marianna Martinelli, Clementina E. Cocuzza, Giovanni Sotgiu, Andrea Piana Pathogens.2023; 12(9): 1169. CrossRef
Human papillomavirus testing using HPV APTIMA® assay and an external cellularity control in self‐collected samples Christophe Pasquier, Stéphanie Raymond, Delphine Duchanois, Karine Sauné, Kevin Oliveira‐Mendes, Christophe Vayssiere, Jacques Izopet Journal of Medical Virology.2023;[Epub] CrossRef
Comparison of Different Self-Sampling Devices for Molecular Detection of Human Papillomavirus (HPV) and Other Sexually Transmitted Infections (STIs): A Pilot Study Illari Sechi, Clementina Cocuzza, Marianna Martinelli, Narcisa Muresu, Santina Castriciano, Giovanni Sotgiu, Andrea Piana Healthcare.2022; 10(3): 459. CrossRef
The Potential of Urine for Human papillomavirus-related Cervical Cancer Prevention Maryame Lamsisi, Guorong Li, Celine Chauleur, Moulay Mustapha Ennaji, Thomas Bourlet Future Virology.2022; 17(7): 495. CrossRef
Evaluation of BD Onclarity™ HPV Assay on Self-Collected Vaginal and First-Void Urine Samples as Compared to Clinician-Collected Cervical Samples: A Pilot Study Marianna Martinelli, Chiara Giubbi, Illari Sechi, Fabio Bottari, Anna Daniela Iacobone, Rosario Musumeci, Federica Perdoni, Narcisa Muresu, Andrea Piana, Robert Fruscio, Fabio Landoni, Clementina Elvezia Cocuzza Diagnostics.2022; 12(12): 3075. CrossRef
Urine HPV in the Context of Genital and Cervical Cancer Screening—An Update of Current Literature Alexandros Daponte, George Michail, Athina-Ioanna Daponte, Nikoletta Daponte, George Valasoulis Cancers.2021; 13(7): 1640. CrossRef
Diagnostic Test Accuracy of First-Void Urine Human Papillomaviruses for Presence Cervical HPV in Women: Systematic Review and Meta-Analysis Peter Bober, Peter Firment, Ján Sabo International Journal of Environmental Research and Public Health.2021; 18(24): 13314. CrossRef